50 research outputs found
The Effects of Pedometers on Body Weight and Metabolic Factors in Patients with Prediabetes
Please download pdf version here
Anti-Mullerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study
Study questions: Can serum anti-Müllerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated features in adolescence and early adulthood?
Summary answer: AMH levels associated well with PCOS-associated features (such as testosterone levels and oligoamenorrhoea) in adolescence, but was not an ideal marker to predict PCOS-associated features in early adulthood.
What is known already: Several studies have reported that there is a strong correlation between antral follicle count and serum AMH levels and that women with PCOS/PCO have significantly higher serum AMH levels than women with normal ovaries. Other studies have reported an association between AMH serum levels and hyperandrogenism in adolescence, but none has prospectively assessed AMH as a risk predictor for developing features of PCOS during adulthood.
Study design, size, duration: A subset of 400 girls was selected from the prospective population-based Northern Finland Birth Cohort 1986 (n = 4567 at age 16 and n = 4503 at age 26). The population has been followed from 1986 to the present.
Participants/material, setting, methods: At age 16, 400 girls (100 from each testosterone quartile: 50 with oligo- or amenorrhoea and 50 with a normal menstrual cycle) were selected at random from the cohort for AMH measurement. Metabolic parameters were also assessed at age 16 in all participants. Postal questionnaires enquired about oligo- or amenorrhoea, hirsutism, contraceptive use and reproductive health at ages 16 and 26.
Main results and role of chance: There was a significant correlation between AMH and testosterone at age 16 (r = 0.36, P < 0.001). AMH levels at age 16 were significantly higher among girls with oligo- or amenorrhoea compared with girls with normal menstrual cycles (35.9 pmol/l [95% CI: 33.2;38.6] versus 27.7 pmol/l [95% CI: 25.0;30.4], P < 0.001). AMH at age 16 was higher in girls who developed hirsutism at age 26 compared with the non-hirsute group (31.4 pmol/l [95% CI 27.1;36.5] versus 25.8 pmol/l [95% CI 23.3;28.6], P = 0.036). AMH at age 16 was also higher in women with PCOS at age 26 compared with the non-PCOS subjects (38.1 pmol/l [95% CI 29.1;48.4] versus 30.2 pmol/l [95% CI 27.9;32.4], P = 0.044). The sensitivity and specificity of the AMH (cut-off 22.5 pmol/l) for predicting PCOS at age 26 was 85.7 and 37.5%, respectively. The addition of testosterone did not significantly improve the accuracy of the test. There was no significant correlation between AMH levels and metabolic indices at age 16.
Implications, reasons for cauntion: AMH is related to oligo- or amenorrhoea in adolescence, but it is not a good marker for metabolic factors. The relatively low rate of participation in the questionnaire at age 26 may also have affected the results. AMH was measured in a subset of the whole cohort. AMH measurement is lacking international standardization and therefore the concentrations and cut-off points are method dependent.
Wider implications for the findings: Using a high enough cut-off value of AMH to predict which adolescents are likely to develop PCOS in adulthood could help to manage the condition from an early age due to a good sensitivity. However, because of its low specificity, it is not an ideal diagnostic marker, and its routine use in clinical practice cannot, at present, be recommended
The Effects of Pedometers on Body Weight and Metabolic Factors in Patients with Prediabetes
Please download pdf version here
Hyperandrogenism, menstrual irregularities and polycystic ovary syndrome:impact on female reproductive and metabolic health from early adulthood until menopause
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age, affecting 5–18% of them. Menstrual irregularities, hyperandrogenemia and obesity are key features in PCOS and they are suggested to be the most important metabolic risks linked to PCOS, but their respective roles are still under debate. Anti-Müllerian hormone (AMH) is involved in sexual differentiation and follicle growth and its level is increased in women with PCOS.
The aims of this project were to clarify the significance of menstrual irregularities, hyperandrogenemia and serum levels of AMH in adolescence as predictive factors of the syndrome and to investigate the respective roles of obesity and hyperandrogenism as metabolic risk factors in women with PCOS from adolescence to late adulthood.
The study populations were the Northern Finland Birth Cohort 1986 (N=3373 women) and a Nordic population including 1553 women with PCOS and 448 controls.
At the age of 16 years, women with menstrual irregularities were more hyperandrogenic compared with women with normal menstrual cycles. Serum AMH levels correlated positively with those of testosterone at this age. They were higher in adolescents with menstrual irregularities compared with those with regular cycles and in women with hirsutism or PCOS at the age of 26 years. However, AMH was not a good marker of metabolic abnormalities in adolescence or a reliable tool to predict PCOS in later life. Androgen levels were higher in women with PCOS throughout life compared with controls. The parameters that best predicted PCOS at all ages were the free androgen index, and androstenedione. Women with PCOS exhibited increased abdominal obesity, altered insulin metabolism, worse lipid profiles and higher blood pressure from early adulthood until menopause compared with controls. The highest prevalence of metabolic syndrome was detected in obese and hyperandrogenic women with PCOS.
In conclusion, irregular menstrual cycles, identified by a simple question at adolescence, represent a good marker of hyperandrogenemia, later metabolic risks and development of PCOS. Due to the persistence of hyperandrogenism and metabolic alterations, the treatment of PCOS should be focused on prevention and treatment of these problems as early as in adolescence in order to decrease future morbidity.Tiivistelmä
Monirakkulainen munasarjaoireyhtymä (polycystic ovary syndrome, PCOS) on lisääntymisikäisten naisten tavallisin (5-18%) hormonaalinen häiriö. Kuukautishäiriöt, mieshormoniylimäärä eli hyperandrogenismi ja lihavuus kuuluvat oireyhtymään oleellisesti ja niiden ajatellaan olevan tärkeimmät PCOS:aan liittyvät metaboliset riskitekijät, vaikkakin niiden tarkat roolit ovat epäselvät. Anti-Müllerian hormoni (AMH) vaikuttaa sukupuolen kehitykseen sikiöaikana sekä munarakkuloiden kypsymiseen hedelmällisessä iässä ja sen pitoisuus on suurentunut PCOS-naisilla.
Tämän väitöskirjan tavoitteena oli selvittää kuukautishäiriöiden, hyperandrogenismin ja AMH-pitoisuuden ennustearvoa PCOS-oireyhtymälle, sekä arvioida lihavuuden ja hyperandrogenismin vaikutusta metabolisiin riskitekijöihin PCOS-naisilla läpi elämän. Tutkimusaineistoina olivat Pohjois-Suomen syntymäkohortti 1986 (N=3373 naista) sekä pohjoismaalainen yhteistyöaineisto, jossa oli 1553 PCOS-naista ja 448 kontrollia.
16-vuotiaiden kuukautishäiriöistä kärsivien naisten mieshormonipitoisuuksien todettiin olevan korkeammat kuin naisilla, joilla kuukautiskierto oli säännöllinen. AMH-tasot korreloituivat positiivisesti testosteronin kanssa 16-vuotiaana, ja pitoisuus oli koholla naisilla, joilla todettiin kuukautishäiriö. AMH-tasot 16-vuotiaana olivat myös korkeampia naisilla, joilla oli 26-vuotiaana PCOS tai hirsutismi. Kuitenkaan AMH-pitoisuus 16-vuotiaana ei korreloinut metabolisten riskitekijöiden kanssa eikä se ollut luotettava parametri ennustamaan PCOS:n kehittymistä. Mieshormonitasot olivat korkeammat PCOS-naisilla läpi elämän verrattuna kontrolleihin. Vapaan mieshormonin indeksit ja androstendioni olivat parhaat parametrit erottamaan PCOS-naiset kontrolleista. PCOS-naisilla todettiin olevan enemmän vyötärölihavuutta, huonompi veren rasvaprofiili ja korkeampi verenpaine varhaisaikuisuudesta menopaussiin saakka. Lihavilla hyperandrogeenisilla naisilla todettiin suurin metabolisen oireyhtymän esiintyvyys.
Yksinkertaisella kysymyksellä selvitetyt kuukautishäiriöt nuoruusiässä todettiin olevan yhteydessä hyperandrogenismiin sekä myöhempiin metabolisiin riskeihin ja PCOS:n kehittymiseen. Jotta pystyttäisiin vähentämään myöhempää sairastavuutta ja kuolleisuutta PCOS-naisilla, oireyhtymän hoidon tulisi keskittyä ennaltaehkäisemään ja hoitamaan lihavuutta, hyperandrogenismia ja metabolisia riskejä jo varhaisaikuisuudessa